Catalog No.
RGN38301
Species reactivity
General
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
1,4,7,10-Dota, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, 2,2',2',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetryl)tetraacetic acid
Concentration
2.44 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
CHEBI:61028
Applications
ELISA
Form
Liquid
Storage buffer
100 mM Pro-Ac, 20 mM Arg, pH 5.0.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
2D12.5
GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer., PMID:40521192
Preirradiation of Spheroids with 225Ac-Trastuzumab Improves Penetration of 225Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails., PMID:40506236
Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy., PMID:40495114
Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody., PMID:40473914
225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer., PMID:40473462
Antibody-Directed Cell Internalization of Targeted Covalent Europium Tag Enables In Situ Kinase Labeling and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Quantification., PMID:40470552
177Lu-Anti-CD25 Antibody for Interleukin-2 Receptor-α-Targeted Radioimmunotherapy of SUDHL1 Lymphomas in Mice., PMID:40408541
Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody., PMID:40405046
Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering., PMID:40293556
Multimodal carcinoembryonic antigen-targeted fluorescence and radio-guided cytoreductive surgery for peritoneal metastases of colorectal origin: single-arm confirmatory trial., PMID:40270484
New Atomic Mass Tags for Enhanced Multiplexing Capability of Multiplexed Ion Beam Imaging Time-of-Flight (MIBI-TOF) Analysis., PMID:40223204
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac., PMID:40183827
Biopsy-Sparing Diagnosis of Coeliac Disease Based on Endomysial Antibody Testing and Clinical Risk Assessment., PMID:40181591
Development and Characterization of the [177Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model., PMID:40088168
MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy., PMID:40015918
Comparison of radiobiological effects induced by radiolabeled antibodies in human cancer cells and fungal cells., PMID:40009794
Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling., PMID:39994098
Deep learning-based organ-wise dosimetry of 64Cu-DOTA-rituximab through only one scanning., PMID:39955298
177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer., PMID:39915118
Tumor Lesion Uptake of [ 177 Lu]Lu-DOTA-Rituximab in Skeletal and Splenic Disease in Diffuse Large B-Cell Lymphoma., PMID:39876085
Exploring utilities of [ 64 Cu]Cu-DOTA-trastuzumab immunoPET in breast cancer: a systematic review and meta-analysis., PMID:39834168
Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18FDG and 64Cu-DOTA-Trastuzumab Positron Emission Tomography Studies., PMID:39808751
Chlorambucil Conjugation Enhances the Potency of Rituximab: Synthesis and Evaluation of the Novel [177Lu]Lu-Labeled Rituximab-Chlorambucil Conjugate toward Therapy of Non-Hodgkin's Lymphoma., PMID:39807673
FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy., PMID:39800373
GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8., PMID:39702399
Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma., PMID:39688699
Radioimmunotherapy combating biofilm-associated infection in vitro., PMID:39678029
Preclinical Comparison of [111In]In- and [225Ac]Ac-DOTA-Trastuzumab IgG, F(ab')2 and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer., PMID:39666273
Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent., PMID:39585568
Phosphonate-Based Aza-Macrocycle Ligands for Low-Temperature, Stable Chelation of Medicinally Relevant Rare Earth Radiometals and Radiofluorination., PMID:39570707
Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma., PMID:39542119
Pharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted 68Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study., PMID:39540871
Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics., PMID:39378827
Visualizing Immune Checkpoint Inhibitors Derived Inflammation in Atherosclerosis., PMID:39328090
Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting., PMID:39266288
Ag2S quantum dot-based magnetic resonance/fluorescence dual-mode imaging nanoprobes for tumor diagnosis., PMID:39240013
Efficient α and β- radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model., PMID:39237746
Development of 52Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2., PMID:39192059
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten., PMID:39168519
Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent., PMID:39159402
Evaluating 64 Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18 F-fluorodeoxyglucose PET/computed tomography., PMID:39155810
Click Chemistry Enables [89Zr]Zr-DOTA Radioimmunoconjugation for Theranostic 89Zr-immunoPET., PMID:39151917
A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements., PMID:39092114
Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of 225Ac-ch806 in Glioblastoma and Colorectal Cancer Xenograft Models., PMID:39054282
177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model., PMID:39051327
Internal dosimetry and biodistribution of indigenously prepared 177 Lu-DOTA-rituximab in lymphoma and other hematological malignancies treated with rituximab., PMID:38975801
Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer., PMID:38963557
Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma., PMID:38948062
On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to Therapy., PMID:38946086
Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging., PMID:38863725
For research use only. Not for human or drug use.
